Decitabine clinical trials
Also written Dacogen and DAC.
Counted the way a researcher would: Decitabine with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Decitabine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Decitabine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 2 May 2006 · DACOGEN · NDA 021790 (FDA, Drugs@FDA)
- European Union
- 20 Sept 2012 · Dacogen · EMEA/H/C/002221 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
276 studies that test it; most in 2017 (19); 1 more planned to start later
| Year | Studies |
|---|---|
| 1995 | 1 |
| 1997 | 1 |
| 1998 | 1 |
| 1999 | 1 |
| 2001 | 2 |
| 2002 | 7 |
| 2003 | 4 |
| 2004 | 6 |
| 2005 | 6 |
| 2006 | 8 |
| 2007 | 7 |
| 2008 | 12 |
| 2009 | 12 |
| 2010 | 10 |
| 2011 | 9 |
| 2012 | 11 |
| 2013 | 14 |
| 2014 | 14 |
| 2015 | 11 |
| 2016 | 12 |
| 2017 | 19 |
| 2018 | 16 |
| 2019 | 11 |
| 2020 | 10 |
| 2021 | 7 |
| 2022 | 11 |
| 2023 | 13 |
| 2024 | 10 |
| 2025 | 13 |
| 2026 | 17 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 33 · Other 244
M.D. Anderson Cancer Center (32) · National Cancer Institute (NCI) (28) · The First Affiliated Hospital of Soochow University (10) · Eisai Inc. (9) · Ruijin Hospital (9) · Chinese PLA General Hospital (7) · Nanfang Hospital, Southern Medical University (6) · Roswell Park Cancer Institute (5)
Often tested with
Tested in the same studies.
Venetoclax (31) · Cytarabine (26) · Azacitidine (17) · Cedazuridine (11) · Vorinostat (8) · Tetrahydrouridine (8) · Sorafenib (5) · Fludarabine (5)
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Decitabine is the comparator. A study of two new drugs counts under both.
- 1Galinpepimut-s · Sellas Life Sciences Group
- 1Clifutinib · Sunshine Lake Pharma Co., Ltd. · next primary completion Nov 2027
Reaching primary completion within a year · 15
Studies that test Decitabine.
- Nov 20265-Azacitidine and Decitabine Epigenetic Therapy for Myeloid MalignanciesEarly Phase 1 · Benjamin Tomlinson
- Dec 2026A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)Phase 1 · Treebough Therapies
- Jan 2027Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic SyndromesPhase 1/2 · M.D. Anderson Cancer Center
- Mar 2027Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell TransplantPhase 1/2 · Benjamin Tomlinson
- Mar 2027Avapritinib With Decitabine in Patients With SM-AHNPhase 1 · H. Lee Moffitt Cancer Center and Research Institute
- Mar 2027A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)Phase 1 · Bio-Path Holdings, Inc.
- Mar 2027Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With VenetoclaxPhase 1 · City of Hope Medical Center
- Mar 2027A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid LeukemiaPhase 1 · National Cancer Institute (NCI)
- Apr 2027Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid MalignanciesPhase 1/2 · M.D. Anderson Cancer Center
- Jun 2027Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor OlutasidenibPhase 1/2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses Decitabine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 277
- Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal HaematopoiesisNot yet recruitingPhase 2Clinical Hub for Interventional Research (CHOIR)NCT07435636Written as Oral Decitabine and Tetrahydrouridine
- Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid MalignanciesRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06383572Written as Decitabine
- A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid LeukemiaRecruitingPhase 1National Cancer Institute (NCI)NCT07012044Written as Decitabine
- Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AMLNot yet recruitingPhase 1Northside Hospital, Inc.NCT07511062Written as Decitabine
- Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage MesotheliomaRecruitingPhase 2National Cancer Institute (NCI)NCT05960773Written as Decitabine/cedazuridine
- A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.RecruitingPhase 1/2University of ChicagoNCT07389239Written as Decitabine
- Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AMLNot yet recruitingPhase 2Rutgers, The State University of New JerseyNCT07867626Written as decitabine/cedazuridine
- Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell TransplantRecruitingPhase 1/2Benjamin TomlinsonNCT06129734Written as Decitabine
- Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease MarkerRecruitingPhase 2The Methodist Hospital Research InstituteNCT07060001Written as Decitabine 20 mg/m²/day for 5 days
- Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor OlutasidenibRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06445959Written as Decitabine
- Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML PatientsRecruitingPhase 2PETHEMA FoundationNCT07507760Written as Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
- A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)RecruitingPhase 2M.D. Anderson Cancer CenterNCT06561074Written as Decitabine
- Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsRecruitingPhase 2University of WashingtonNCT04282187Written as Decitabine
- Hydrochloroquinine & Decitabine With Venetoclax in AMLNot yet recruitingPhase 1Rutgers, The State University of New JerseyNCT07814339Written as Oral Decitabine/cedazuridine
- A Study of VABu Conditioning Regimen in Allo-HSCT for AML PatientsNot yet recruitingNot applicableThe First Affiliated Hospital of Soochow UniversityNCT07762508Written as Decitabine 20 mg/m²/day for 5 days
- Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative NeoplasmsRecruitingPhase 2University of WashingtonNCT07148947Written as Decitabine
- New Genotype-guided Treatment in Newly Diagnosed PTCLNot yet recruitingPhase 1/2Ruijin HospitalNCT07706959Written as Decitabine plus Selinexor with CHOP
- Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)RecruitingPhase 2M.D. Anderson Cancer CenterNCT01515527Written as Decitabine
- Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck CancerRecruitingPhase 1Mayo ClinicNCT06997094Written as Decitabine
- Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal CancerNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07691632Written as Serplulimab + Decitabine + CAPOX (Oxaliplatin + Capecitabine)
See all 277 studies that test Decitabine →
Given beside what is tested · 107 — Decitabine is usual care or a partner of the new treatment
- ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDSRecruitingPhase 1Washington University School of MedicineNCT07617363Written as Decitabine
- Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDSRecruitingPhase 2Beijing 302 HospitalNCT07238686Written as Azacitidine (AZA) or Decitabine (DAC)
- Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingPhase 2M.D. Anderson Cancer CenterNCT00801489Written as Decitabine
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic LeukemiaRecruitingPhase 2Mayo ClinicNCT03418038Written as Decitabine
- A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid LeukemiaRecruitingPhase 1M.D. Anderson Cancer CenterNCT06401603Written as Decitabine
- A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid MalignanciesRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06930651Written as Decitabine
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingPhase 2/3Beat AML, LLCNCT03013998Written as Decitabine (BAML-16-001-S5)
- High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)RecruitingPhase 1Kittika PoonsombudlertNCT07177079Written as Decitabine
- Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCLNot yet recruitingPhase 1/2Ruijin HospitalNCT07493330Written as Zeprumetostat+Decitabine
- Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid MalignanciesRecruitingPhase 1University of Alabama at BirminghamNCT07044544Written as Decitabine
- FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid LeukemiaRecruitingPhase 1Montefiore Medical CenterNCT07283094Written as Decitabine
- Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRDRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06511882Written as Decitabine
- Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory MalignanciesRecruitingPhase 1/2Han weidongNCT02961101Written as Decitabine
- Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic SyndromeRecruitingPhase 1Syntrix Biosystems, Inc.NCT04245397Written as Decitabine
- Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)Enrolling by invitationEarly Phase 1BGI, ChinaNCT06499025Written as Decitabine Injection
- Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies)Not yet recruitingPhase 2Wuhan Union Hospital, ChinaNCT07007767Written as Decitabine
- Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse PreventionRecruitingPhase 2Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT06686108Written as Decitabine (DAC)
- Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AMLRecruitingPhase 2Bio-Path Holdings, Inc.NCT02781883Written as BP1001 plus decitabine
- Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT MutationRecruitingPhase 2Children's Hospital of Soochow UniversityNCT06316960Written as Decitabine Injection
- Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDSRecruitingPhase 2Anhui Provincial HospitalNCT06109064Written as Decetabine
Showing 20 of 107.
As the comparator · 6 — what is tested is compared with Decitabine
- HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AMLRecruitingPhase 3Sunshine Lake Pharma Co., Ltd.NCT05586074Written as Decitabine
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th SalvageTerminatedPhase 3Delta-Fly Pharma, Inc.NCT03926624Written as Decitabine
- Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2Active, not recruitingPhase 3Sellas Life Sciences GroupNCT04229979Written as Decitabine
- Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART TrialSuspendedPhase 2Johns Hopkins UniversityNCT04482621Written as Decitabine
- Trial of Decitabine in Patients With Acute Myeloid LeukemiaCompletedPhase 3Eisai Inc.NCT00260832Written as Dacogen (decitabine) only
- Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDSStatus unknownPhase 2/3Xiao LiNCT01417767Written as 5-aza-deoxycytidine
What changed recently
From the registry's own updates since Oct 17, 2026.
Results posted1
- Decitabine for Poor Graft Function Post Allo-HSCTOct 23, 2026NCT05907499
Codes
What other systems call Decitabine · ClinicalTrials.gg INT006664
- MeSH (NLM) D000077209DecitabineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 776B62CQ27DECITABINEConfirmed FDA, NLM, Wikidata
- RxNorm 15657Confirmed FDA, Wikidata
- Wikidata Q1181878decitabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C981DecitabineOne source FDA
- DrugBank DB01262One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077209 | Decitabine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 776B62CQ27 | DECITABINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 15657 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1181878 | decitabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C981 | Decitabine | One source FDA |
| DrugBank | DB01262 | — | One source Wikidata |
Also registered as decitabine mesylate (UNII 6U3LPL9PRN).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.